21 CFR 211.67
Every DSRV article whose Regulatory Snapshot cites 21 CFR 211.67: the enforcement case behind it, the inspection exposure it created, and what the desk would do about it.
- What has FDA cited under 21 CFR 211.67?
- 2 DSRV articles cite 21 CFR 211.67. Enforcement cases behind them: FDA Warning Letter 320-26-60 (case 721592) to Chemco Corporation, April 7, 2026, following an August 11 to 22, 2025 inspection of its Miami Lakes, Florida facility; ICH Q9(R1) Quality Risk Management (revised 2023); recurring FDA 483 cleaning-validation observations. Inspection exposure across them: 2 high.
- What does DSRV recommend for 21 CFR 211.67?
- From the newest article (FDA Tied Residue, Cleaning Validation, and Component Controls at Chemco): When residue, missing validation, and weak identity testing appear in one facility, FDA stops scoring individual gaps and asks whether the quality system can detect and correct risk before the investigator does, which is why disconnected lane-by-lane CAPAs fail in these cases. DSRV's matching service is the Cleaning Validation Risk Review, delivered through controlled intake at /submit. DSRV is decision support, not legal advice; verify against the official source each article names.
- 6 min readHigh exposure
FDA Tied Residue, Cleaning Validation, and Component Controls at Chemco
FDA's April 2026 Chemco warning letter links visible residue, missing cleaning validation for shared equipment, and inadequate incoming component identity testing into one quality-system control failure.
- Case
- FDA Warning Letter 320-26-60 (case 721592) to Chemco Corporation, April 7, 2026, following an August 11 to 22, 2025 inspection of its Miami Lakes, Florida facility.
- DSRV take
- When residue, missing validation, and weak identity testing appear in one facility, FDA stops scoring individual gaps and asks whether the quality system can detect and correct risk before the investigator does, which is why disconnected lane-by-lane CAPAs fail in these cases.
- 11 min readHigh exposure
Risk-Based Cleaning Validation: Applying ICH Q9 Principles in Practice
Cleaning validation remains one of the most inspection-cited areas in pharmaceutical manufacturing. This article explores how a risk-based framework under ICH Q9 Rev.1 can rationalise your validation strategy.
- Case
- ICH Q9(R1) Quality Risk Management (revised 2023); recurring FDA 483 cleaning-validation observations.
- DSRV take
- A risk-based cleaning program is defensible only when worst-case selection and acceptance limits trace back to a documented risk assessment.
Cleaning Validation Risk Review
Bring the document that has to hold up under 21 CFR 211.67. DSRV maps the evidence, names the gaps, and routes judgment calls to human review. Controlled intake, no public file upload.
Regulatory intelligence and interpretation, not legal advice. Verify against the official FDA or ICH source each article names.